Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Cyclophosphamide with Carfilzomib and Dexamethasone in RRMM
NCT05909826Phase 2Not yet recruiting
- Start
- Jul 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in multiple myeloma (MM). Primary endpoint: Very Good Partial Response. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
cyclophosphamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05909826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05909826.